This trial will test whether a new imaging agent, 18F-Clofarabine, can be used to show pyrimidine metabolism in order to better predict whether cancer drugs will be effective.
1 Primary · 4 Secondary · Reporting Duration: up to 60 minutes after CFA PET
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: 18F-Clofarabine · No Placebo Group · Phase < 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
Met criteria | 100.0% |